Studying How Blocking CaV1.2 Calcium Channels Affects Sleep Health Under 5G Exposure in Adults Aged 20 to 40

What this Trial Is About

Researchers are investigating how electromagnetic fields EMFs from 5G technology affect sleep health, focusing on a specific brain protein called CaV1.2, a voltage-gated calcium channel. This protein may play a role in how 5G influences sleep, especially for people with a certain genetic variant. The study aims to see if blocking this channel with the drug nimodipine can reduce or stop the impact of 5G on sleep in healthy adults with the genetic variant. The study involves a large genetic screening to find participants with the targeted genetic variant, followed by a sleep screening night. Then, participants undergo four experimental nights where they are exposed to either an active 5G field or a sham inactive field, combined with either nimodipine or a placebo. The drug or placebo is given orally 45 minutes before exposure, and the study uses a double-blind design with 24 different sequences of drug and exposure combinations randomly assigned to participants. During the study nights, participants have their sleep monitored using polysomnography and high-density EEG during wakefulness. Researchers also measure heart rate, cognitive and neuropsychiatric functions, and various sleep characteristics like sleep spindle frequency and EEG power spectra. The study includes assessments before and after sleep, with at least three days between sessions to avoid overlap. The total duration covers screening, genetic testing, and multiple experimental sessions to understand the role of CaV1.2 in 5G effects on sleep.

A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans